Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Buzz on the Bullboards: The Top Last-Minute Movers of 2021

Expecting the markets to be relaxed heading into the holidays? Hardly. Many investors and brokers know that this is the time to shine. With every twist and turn the global economy has been throwing our way, the right move is staying active. This past week, it seems ma...
Stockhouse Editorial | December 7, 2021 |

Arbutus Biopharma Trades 25% Higher on Phase 1 Hepatitis B Results

Shares of Arbutus Biopharma traded higher after the company reported significant and continuous reduction in HBsAg in 12 chronic hepatitis B subjects using 60 mg dosage of its AB-729 drug. Clinical-stage biopharmaceutical company Arbutus Biopharma Corp. (ABUS:NASD...
Streetwise Reports | May 20, 2020 |

Buzz on the Bullboards: Has the November rally paid off?

Once the U.S. Thanksgiving passes, the mood in North American markets shifts as investors contend with holidays, gifts, and vacations on one hand, with the end of their fiscal years on the other. Companies also look to end the calendar year on a positive note, and any...
Jonathon Brown | November 30, 2023 |

Regeneron Reports Positive Phase 3 Dupixent Data; Gains EU Approval Recommendation

Regeneron Pharmaceuticals published positive results from two U.S. Phase 3 trials evaluating the safety and efficacy of Dupixent (dupilumab) in adults with recurring severe chronic rhinosinusitis with nasal polyps. The European Medicines Agency's Committee for Medicinal Produc...
Streetwise Reports | September 24, 2019 |

A Topical Solution for Chronic Pain

Pain impedes the life of millions around the world, and the market for topical creams to treat this pain is growing at an accelerated rate as people choose to treat pain directly vs ingesting pain killers. Some analysts, such as those at Allied Market Research, project that ...
Jonathon Brown | May 2, 2022 |

Buzz on the Bullboards: Volatility persists in the face of economic indicators

This week has proven to be a challenging one for investors on both sides of the border. Canada’s main stock index struggled to gain traction as Statistics Canada reported another rise in the Industrial Product Price Index for April, reflecting ongoing...
Jonathon Brown | 2 days ago |

Inside Update on Gold with Veteran Experts

Stockhouse readers and investors know Mickey Fulp and Dr. Kal Kotecha . And, for years, they’ve trusted what these two seasoned gold mining analysts have had to say when it comes to market trends…from the bulls to the bears. And even zombie miners! ...
Dave Jackson | March 19, 2020 |

Reata Pharma Announces $350 Million Strategic Investment from Blackstone Life Sciences

Shares of Reata Pharmaceuticals traded 30% higher after reporting that Blackstone Life Sciences will invest $350 million in the company to advance bardoxolone methyl as a potential therapy for Alport syndrome and other rare and serious chronic kidney diseases. Clin...
Streetwise Reports | June 12, 2020 |

Dova Pharma Shares Rise 38% on Swedish Firm Takeover Offer

Shares of Dova Pharmaceuticals opened 38% higher today on news that the firm will be acquired by Swedish Orphan Biovitrum. The deal is reportedly valued at $915 million or $29/share. This morning Durham, N.C.-based Dova Pharmaceuticals Inc. (DOVA:NASDAQ) announced ...
Streetwise Reports | October 1, 2019 |

Reliq Re-establishes Itself as Community Care Technology Leader ...

Reliq Re-establishes Itself as Community Care Technology Leader Amidst Sweeping Federal Medicare/Medicaid Changes A shift in the industry leads to big new contracts and parabolic stock performance for this small cap. A sweeping new development in what federal...
Streetwise Reports | November 14, 2019 |
1 2 3 4 5 6 7 8 9 10